Steve O'Loughlin

Educational Background

Steve O'Loughlin is a seasoned financial executive with a strong focus on the life sciences and biopharmaceutical industries. His educational foundation includes a Bachelor of Science degree in Finance from Ramapo College of New Jersey. Additionally, he is a Level III Candidate in the Chartered Financial Analyst (CFA) Program, signifying his successful completion of the program's first two levels, which covers a rigorous curriculum in financial analysis and ethical standards.

Career Trajectory

Steve's career trajectory showcases his expertise in various finance roles, particularly in the life sciences sector. He began his career in life sciences investment banking, serving as Assistant Vice President at Jesup & Lamont from February 2008 to August 2009. He then moved on to work at Forge Financial Group from January 2009 to July 2010, further honing his skills in this niche area.

In June 2010, Steve became Regional Manager at Lucid, Inc. (now Caliber ID), where he was responsible for marketing innovative imaging solutions that could visualize tissue at the cellular level. His role there lasted until June 2012 and was followed by a position as Vice President of Corporate Finance and Development at Protea Biosciences. At Protea, Steve worked from September 2012 to May 2015, contributing to the development of mass spectrometry molecular imaging technologies crucial for pharmaceutical and life science research.

Current Role

Since October 2015, Steve has been serving as the Chief Financial Officer at Actinium Pharmaceuticals, Inc., based in the Greater New York City Area. Actinium Pharmaceuticals focuses on developing targeted cancer therapies, utilizing monoclonal antibodies to deliver radioisotopes directly to cancer cells. Steve plays a crucial role in overseeing the company's financial operations and driving its strategic growth. Actinium’s lead product, Iomab-B, aims to prepare patients for hematopoietic stem cell transplants with fewer toxicities compared to traditional methods, and other promising products like Actimab-A and Actimab-M are in the pipeline targeting conditions such as Acute Myeloid Leukemia and multiple myeloma.

Professional Skills and Network

Steve's career is characterized by his extensive skills in strategic planning, corporate development, investment banking, and financial modeling. He is highly reputed and connected within the biotechnology and financial industries, with a follower count of 1,667 on LinkedIn reflecting his influence and network.

Contributions to the Industry

Throughout his career, Steve has demonstrated a strong track record in enhancing corporate value, driving business success, and contributing to the development of innovative medical solutions. His extensive experience and dedication to his field make him a highly valuable asset in the financial and life sciences sectors.